Page 9, Types of outcome measures: I would not recommend trying to consider costs within this review. Cost analyses are complex, should also take into account the efficacy of interventions (e.g. approaches such as costeffectiveness, cost benefit. cost-minimisation etc.). Furthermore, costs are very specific to setting / country and will probably be out of date very soon after the review is published.
Page 11, Data Extraction and Management: "Outcomes: details of the major and minor outcomes: methods used to measure outcomes, mean scores and standard deviations of outcomes direction of effect for each outcome; and adverse events" Does this mean that all outcomes are measured as continuous data except for adverse events? What about 'risk of x-ray exposure'? Risk implies dichotomous data to me.
Page 12, Data Extraction and Management: "…when data were transformed or estimated from a graph." Please clarify the transformations that you intend to use and please justify that the transformations are appropriate For example, there are formulas to convert interquartile ranges to standard deviations, but it is generally not advisable to use such transformations when the data is very skewed, see Cochrane Handbook Chapter 7.7.3.5: https://handbook-5-1.cochrane.org/chapter_7/7_7_3_5_mediansand_interquartile_ran ges.htm Page 12, Assessment of Risk of Bias in Included Studies: Please note that tools which assess 'risk of bias' are suitable only for RCTs. Tools for non-randomised designs assess 'quality.' Please edit to 'risk of bias or quality' throughout this section.
It may also help to have subheadings for the approaches for randomised and non-randomised studies? Also please make sure that you are describing the assessment approach for all designscurrently this section only really mentions the details for RCTs Page 13, Assessment of Risk of Bias in Included Studies: It is fine if the authors do not wish to use the ROBINS-1 tool (the NIH/NHLBI tools seem appropriate), but for information, the tool is no longer undergoing validation.
ROBINS-1 is now being used within Cochrane reviews but is not yet mandatory as the tool is not yet implemented within the Cochrane software.
Page 14, Measures of treatment effect: "We will calculate the relative difference in the change from baseline as the absolute benefit divided by the baseline mean of the control group, and express as a percentage."
To clarify, the outcomes listed above are all being measured as relative change from baseline of each of the measures? Or is this sentence referring to the back-transformation of SMD? Page 14, Measures of treatment effect: I do not recommend presenting NNT for adverse event outcomes. It would actually be the Number Needed to Harm for an adverse events outcome which is a difficult measure to interpret and these measures are open to misinterpretation: https://www.ncbi.nlm.nih.gov/pubmed/19438480 I suggest presenting an effect measure such as Risk Ratio or Risk Difference (with confidence intervals) and results will also be presented as 'Absolute anticipated effects' in the Summary of Finding tables described below, which gives a more 'real world' interpretation per 100 people Page 16, Data Synthesis: "For dichotomous outcomes, we will report the percentage improvement." I don't understand this sentence for adverse events outcomes Page 16-17: Please note that some of the analyses here are not technically 'subgroup' analyses. There must be no overlap across subgroups to test for differences between subgroups (e.g. age<65 and age>65, severity stages).
Where studies may contribute data to more than one 'subgroup' e.g. the analysis comparing short-term, intermediate-term, longterm, the test of subgroups cannot be used (but it can be useful to present the time points on the same forest plot without pooling across time points for visual interpretation.
Please edit to clarify this within the section Page 17, Sensitivity analysis: "To examine the robustness of the findings to potential selection, detection and attrition biases, we will conduct sensitivity analyses."
It is stated within the Data Synthesis that the primary analysis approach for some of the outcomes will be limited to studies at low risk of selection and detection bias. Please clarify which outcomes(s) the sensitivity analysis applies to.
Page 17, Summary of evidence: "We will compile two 'Summary of findings' tables using GRADEpro software (GRADEpro GDT 2015) to summarize the effects of stretching and bracing on the major outcomes described above." I would suggest that randomised and non-randomised evidence for stretching and bracing should be presented in different tables (so 4 tables may be required in total). It would be very difficult to make a GRADE quality of the evidence judgement based on randomised and non-randomised evidence combined. The authors describe a detailed and comprehensive systematic review protocol. I have the following comments for the attention of the authors:
REVIEWER
Comment 1: Page 8, Comparisons: "We will include all studies for which the effects of the intervention can be isolated." I interpreted this to mean that only studies will be included where the intervention is given alone, however within the Subgroup Analysis section, the use of adjunctive treatments is mentioned.
Please clarify what is meant by 'isolated.'
Response: Studies for which the effects can be isolated indicates studies in which the only difference between the group treated with stretching and the comparator group is the stretching treatment. For example, Hypothetical study 1:
Hypothetical study 2:  Group 1: New stretching regimen plus analgesics  Group 2: Analgesics only Hypothetical study 3:  Group 1: New stretching regimen plus adjunctive ultrasound  Group 2: Ultrasound only
For each of these studies, the effects of stretching can be isolated and they would be included.
Conversely, in another example:
Hypothetical study 4:  Group 1: No intervention  Group 2: Holistic regimen (ultrasound, functional electrical stimulation, psychological counselling, stretching)
In this case, the effect of stretching alone cannot be isolated and so the study would be excluded.
We have added a clarifying point to this section:
Comparisons "We will include all studies for which the effects of the intervention can be isolated. That is, we will include studies if they compared a stretching or bracing intervention alone or in combination to any other treatment (e.g. stretching plus ultrasound, versus ultrasound only) or placebo, such that differences between the groups can be attributed solely to the stretching intervention."
Comment 2: Page 9, Types of outcome measures: A lot of primary outcomes are specified in this section.
It is recommended to have no more than three primary outcomes with at least one outcome measuring benefit of the intervention and at least one outcome measuring any harm of the intervention, see Chapter 5. ), radiographic changes, post-arthroplasty outcomes (if stretching was performed pre-operatively, then participants underwent arthroplasty), risk of x-ray exposure and patients who withdrew because of adverse events. Outcome assessment can be measured at any time following intervention. We will group outcomes by three main timing categories: short-term intervention (less than 3 months), intermediate-term (3 to 6 months) and long-term intervention (6 months or greater)." Comment 3: Page 9, Types of outcome measures: I would not recommend trying to consider costs within this review. Cost analyses are complex, should also take into account the efficacy of interventions (e.g. approaches such as cost-effectiveness, cost benefit. cost-minimisation etc.). Furthermore, costs are very specific to setting / country and will probably be out of date very soon after the review is published.
Response: This is a helpful point. "cost of radiology" has been removed. Comment 4: Page 11, Data Extraction and Management: "Outcomes: details of the major and minor outcomes: methods used to measure outcomes, mean scores and standard deviations of outcomes direction of effect for each outcome; and adverse events" Does this mean that all outcomes are measured as continuous data except for adverse events? What about 'risk of x-ray exposure'? Risk implies dichotomous data to me.
Response: Agree that adverse event would often be dichotomous. Adverse events has now been given a separate line.
Comment 5: Page 12, Data Extraction and Management: "…when data were transformed or estimated from a graph." Please clarify the transformations that you intend to use and please justify that the transformations are appropriate For example, there are formulas to convert interquartile ranges to standard deviations, but it is generally not advisable to use such transformations when the data is very skewed, see Cochrane Handbook Chapter 7.7.3.5: https://handbook-5-1.cochrane.org/chapter_7/7_7_3_5_mediansand_interquartile_ranges.htm
Response: Agree that it may not be appropriate to convert median and interquartile ranges to means and standard deviations. We have removed "transform" from the text. If data on means and standard deviations are only reported graphically, we will contact the study's authors to obtain the quantitative data and we will note this is the "Characteristics of included studies". "We will note in the 'Characteristics of included studies' table if outcome data were not reported in a usable way." AND "Dealing with missing data We will contact investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible. This will be noted in the 'Characteristics of included studies' table." Comment 6: Page 12, Assessment of Risk of Bias in Included Studies: Please note that tools which assess 'risk of bias' are suitable only for RCTs. Tools for non-randomised designs assess 'quality.' Please edit to 'risk of bias or quality' throughout this section.
It may also help to have subheadings for the approaches for randomised and non-randomised studies? Also please make sure that you are describing the assessment approach for all designscurrently this section only really mentions the details for RCTs
Response:
The section has been re-written accordingly: "Randomised controlled trials: Two review authors (BG and EG) will independently assess the risk of bias of the included studies. We will assess the following methodological domains: sequence generation, allocation sequence concealment, blinding of participants and treating clinicians, blinding of outcome assessors for objective outcomes, blinding of outcome assessors for self-report outcomes, incomplete outcome data, selective outcome reporting, and other potential threats to validity. 48 We will judge these domains explicitly using the following criteria: 'Yes' = low risk of bias; 'No' = high risk of bias; 'Unclear' = either lack of information or uncertainty over the potential for bias. When studies report incomplete data in more than 15% of participants, we will deem them as having high risk of bias from incomplete outcome data. We will summarize the 'Risk of bias' judgements across different studies for each of the domains listed. We will consider blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be different than for a patient-reported pain scale). We will resolve disagreements by discussion or, if necessary, a third (VW) will arbitrate. We will present the figures generated by the 'Risk of bias' tool to provide summary assessments of the risk of bias. For RCTs, we will use the Cochrane risk of bias tool to assess the for sources of bias.
48
Non-randomised studies Two review authors (BG and EG) will independently assess the risk of bias of the included studies. We will present the risk of bias for non-randomised studies in a separate table from RCTs. For CCTs and CBAs we will assess the risk of bias according to the domains outlined in the Cochrane effective practice and organization of care (EPOC) data collection checklist. We will judge these domains explicitly using the following criteria: 'Yes' = low risk of bias; 'No' = high risk of bias; 'Unclear' = either lack of information or uncertainty over the potential for bias. When studies report incomplete data in more than 15% of participants, we will deem them as having high risk of bias from incomplete outcome data. We will resolve disagreements by discussion or, if necessary, a third (VW) will arbitrate.
For observational and case-control study designs, study quality will be assessed using the appropriate National Institute of Health/National Heart Lung and Blood Institute (NIH/NHLBI) Study Quality Assessment Tools, and associated criteria. 49 These assessment tools were selected as we anticipate that the types of study designs included in our review will be broad. Rather than use tools from multiple sources (making comparison of quality assessment across studies difficult), the NIH/NHLBI provides a specific evaluation tool for each of the non-randomised, non-controlled study designs listed in our inclusion criteria." Response: Comment appreciated. This section has been reworded: "Rather than use tools from multiple sources (making comparison of quality assessment across studies difficult), the NIH/NHLBI provides a specific evaluation tool for each of the non-randomised, non-controlled study designs listed in our inclusion criteria." Comment 8: Page 14, Measures of treatment effect: "We will calculate the relative difference in the change from baseline as the absolute benefit divided by the baseline mean of the control group, and express as a percentage."
To clarify, the outcomes listed above are all being measured as relative change from baseline of each of the measures? Or is this sentence referring to the back-transformation of SMD?
Response: Agree that this was confusing (possibly missed from a previous draft). This sentence has been removed. Comment 9: Page 14, Measures of treatment effect: I do not recommend presenting NNT for adverse event outcomes. It would actually be the Number Needed to Harm for an adverse events outcome which is a difficult measure to interpret and these measures are open to misinterpretation: https://www.ncbi.nlm.nih.gov/pubmed/19438480 I suggest presenting an effect measure such as Risk Ratio or Risk Difference (with confidence intervals) and results will also be presented as 'Absolute anticipated effects' in the Summary of Finding tables described below, which gives a more 'real world' interpretation per 100 people Response: This section has been re-written: "For dichotomous outcomes, such as adverse event occurrence, the risk difference will be calculated from the treatment group event rate minus control group event rate and will include 95% confidence intervals." Comment 10: Page 16, Data Synthesis: "For dichotomous outcomes, we will report the percentage improvement." I don't understand this sentence for adverse events outcomes
Response: This has been clarified: ". For dichotomous outcomes, we will report the percentage of participants that experienced improvement (or adverse event) with standard deviation."
Comment 11: Page 16-17: Please note that some of the analyses here are not technically 'subgroup' analyses. There must be no overlap across subgroups to test for differences between subgroups (e.g. age<65 and age>65, severity stages).
Where studies may contribute data to more than one 'subgroup' e.g. the analysis comparing shortterm, intermediate-term, long-term, the test of subgroups cannot be used (but it can be useful to present the time points on the same forest plot without pooling across time points for visual interpretation.
Please edit to clarify this within the section Response: Any overlap has been removed:
• compare the effects of short-term intervention (< 3 months' treatment) with intermediate (3-6 months' treatment) and long-term (>6 months' treatment);
• evaluate the effects of important OA-associated demographic factors such as sex (male versus female) and age (age <65 years versus age ≥65 years);
• evaluate the effect of radiographic OA severity (Kellgren and Lawrence stages 1-2 versus Kellgren and Lawrence stages 3-4)
We have updated the last paragraph of the Subgroup analysis and investigation of heterogeneity section: "For studies that contribute data to more than one subgroup (e.g. short-intermediate-and long-term treatment arms in the same study) but do not provide subgroup population data, formal pooling and statistical testing for subgroup interactions will not be performed; however, data may be presented graphically for visual interpretation."
Comment 12: Page 17, Sensitivity analysis: "To examine the robustness of the findings to potential selection, detection and attrition biases, we will conduct sensitivity analyses."
Response:
The statement in the Data Synthesis section has been removed: "The primary analysis for our reviews for self-reported outcomes (e.g. outcomes such as pain, function, quality of life) will be restricted to trials at low risk of detection and selection bias."
We have clarified the outcomes for which sensitivity analysis will be performed in the Sensitivity analysis section: "The sensitivity analyses will examine the effects of randomization, allocation concealment, blinding of assessors (if not a self-reported measure) and completeness of outcome data on range of motion, pain, stiffness and functional outcomes." These are primary outcome measures and those assessed clinically on validated scales such as the WOMAC and KOOS.
Comment 13: Page 17, Summary of evidence: "We will compile two 'Summary of findings' tables using GRADEpro software (GRADEpro GDT 2015) to summarize the effects of stretching and bracing on the major outcomes described above." I would suggest that randomised and non-randomised evidence for stretching and bracing should be presented in different tables (so 4 tables may be required in total). It would be very difficult to make a GRADE quality of the evidence judgement based on randomised and non-randomised evidence combined.
Response: Agreed. The section has been reworded: "We will compile 'Summary of findings' tables using GRADEpro software (GRADEpro GDT 2015). We will summarize the effects of stretching and bracing separately for the major outcomes described above. For both stretching and bracing, we will also separately present tables for RCT and non-RCT summary of findings. We will justify all decisions to down-or up-grade the quality of studies using footnotes and we will make comments to aid reader's understanding of the review where necessary.
"
The authors thank Reviewer 1 for taking the time to provide these insightful comments, which have helped strengthen our protocol.
Reviewer 2 Reviewer Name: LUCIANE CRUZ LOPES, full professor Institution and Country: Pharmaceutical Science Graduate Course, University of Sorocaba, Brazil Please state any competing interests or state 'None declared': None
In general: The protocol aims to evaluate the effectiveness of stretching and bracing on native (nonoperated) joint contractures in people with radiographically-diagnosed OA. The central theme of the protocol is interesting and RS was not found involving the two types of intervention in patients with OA. The protocol version is not registered in Prospero yet. The authors addressed a narrow question that carefully should be analyzed. Below I described my concerns. Thanks.
Comment 1:
The method in abstract needs to be a bit more complete (include GRADE)
Response:
The abstract has been re-written to include more information regarding methods and analysis, while maintain the appropriate word count.
Comment 2:
To better specify the limitations of the methodological points in the bullets
Response:
We have included more specific detail regarding the potential limitations we may encounter in this study: "Different types of stretching and bracing methods, as well as varying severity of OA in different joints may result in heterogeneity in the outcomes presented by included studies, which may in turn make it difficult to perform meta-analysis. A lack of high-quality trials that meet our inclusion criteria might make it difficult to draw conclusions supported by high-quality evidence with low risk of bias." Comment 3: What is the prevalence of contracture in OA? Explain better in the background section Response: Information regarding the prevalence of contractures in OA has been added to the Introduction: "Many patients with OA develop contractures of their affected joints, characterized by a restriction in the joint's passive range of motion (ROM). [7] [8] [9] [10] [11] [12] One-third to half of patients with knee OA will develop a contracture in the OA-affected joint, 7-13 as will up to 40% of patients with hip OA.
" Comment 4:
The exclusion criterion of studies is unclear
Response: More detail has been added in order to clarify: "Studies including participants with inflammatory arthropathies (e.g. seropositive arthropathies such as rheumatoid arthritis or systemic lupus erythematosus, seronegative arthropathies such as psoriatic arthritis or ankylosing spondylitis, or crystal arthropathies such as gout) for which the treatment effect on primary OA-affected participants cannot be isolated will be excluded. To maintain our focus on preoperative OA contracture treatment, participants that receive treatment after post-joint arthroplasty will also be excluded."
Comment 5: Why did the authors choose to include observational study? This inclusion will down grade the quality of the evidence. Justify why the authors will not only include RCT
Response: Based on a scoping review, we found very few RCTs that would have met our inclusion criteria. We agree that inclusion of observational studies could downgrade the quality of evidence; however, we were also concerned about having too few studies to include in our review. In order to address this issue, we plan to report outcomes and effect sizes of RCTs and non-RCTs separately (please also see Reviewer 1, Comment 13).
Comment 6: Explain better the hypotheses that will be established and considered as factors of heterogeneity (anticipate what is expected).
Response:
We have included a hypothesis at the end of the background section: "It is our hypothesis that the evidence evaluating the effectiveness of stretching for the treatment of OA-related contractures will be heterogeneous in nature and of variable quality."
